GenSight Biologics : Nominees to the Board of Directors

GENSIGHT BIOLOGICS

A French Société Anonyme (corporation) with share capital of 820,684.05 Euros 74 rue du Faubourg Saint Antoine 75012 Paris

751 164 757 - Paris Trade and Companies Registry

NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF APRIL 29,

2020

USUAL NAME: Peter GOODFELLOW, Ph.D

PERSONAL HOME ADDRESS: 14 Parliament Hill, London, NW3 2SY, UK

DATE AND PLACE OF BIRTH: August 4, 1951 - London, UK

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

PETER GOODFELLOW, PH.D. has served as a director since June 2014. Dr. Goodfellow is a scientific consultant for Abingworth, Sanofi and the Bill and Melinda Gates Foundation.

Dr. Goodfellow was previously the Balfour Professor of Genetics at Cambridge University before working for SmithKline Beecham (later GlaxoSmithKline) as head of research. He has founded several biotechnology companies and has sat on the boards of Prosensa deCode and several medical charities.

Dr. Goodfellow currently serves as the chairman of the Board of Directors of GammaDelta Therapeutics, a biotech developing novel immunotherapies for cancer and other diseases.

Dr. Goodfellow holds doctorates from Oxford and Bristol Universities.

OFFICES IN THE COMPANY:

Independent member of the Board of Directors, Chair of the Nominations Committee

NUMBER OF SHARES OF THE CORPORATION OWNED: 0

GENSIGHT BIOLOGICS

A French Société Anonyme (corporation) with share capital of 820,684.05 Euros 74 rue du Faubourg Saint Antoine 75012 Paris

751 164 757 - Paris Trade and Companies Registry

NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF APRIL 29,

2020

USUAL NAME: Natalie MOUNT, PhD

PERSONAL HOME ADDRESS: 29 Broad Oak Road, Canterbury, Kent. CT2 7PL

DATE AND PLACE OF BIRTH: July 5, 1972 - Oxford, UK

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

NATALIE MOUNT, PH.D, has served as a director since May 2017. Dr. Mount is currently Chief Scientific Officer, leading Research and Development activities, at GammaDelta Therapeutics.

Previously, she was Chief Clinical Officer at the Cell and Gene Therapy Catapult, where she was responsible for the translational, regulatory and clinical development activities for a wide range of cell and gene therapies.

Prior to that, Dr. Mount spent 16 years at Pfizer leading development activities across various therapeutic areas, including cell based therapies in the Regenerative Medicine Unit. Dr. Mount has also sat on the boards of directors of the Cell and Gene Therapy Catapult, CTTCR and Chimeric Therapeutics.

Dr. Mount has a first class degree in Natural Sciences from the University of Cambridge and a Ph.D. from University College, London.

OFFICES IN THE COMPANY:

Independent member of the Board of Directors, member of the Nominations Committee

NUMBER OF SHARES OF THE CORPORATION OWNED: 0